| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2016 | CHARLESSON, LLC | 5301 BEVERLY TER | OKLAHOMA CITY | OK | 73105-1806 | OKLAHOMA | USA | R43EY026326 | Fenofibrate Eye Drop for the Treatment of Diabetic Retinopathy | 000 | 1 | NIH | 12/31/2018 | $0 |
| | 2019 | 2016 | CHARLESSON, LLC | 5301 BEVERLY TER | OKLAHOMA CITY | OK | 73105-1806 | OKLAHOMA | USA | R44EY021973 | Developing A Novel Therapy for Diabetic Retinopathy | 000 | 3 | NIH | 12/31/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2015 | CHARLESSON, LLC | 5301 BEVERLY TER | OKLAHOMA CITY | OK | 73105-1806 | OKLAHOMA | USA | R43EY025157 | A Novel Therapeutic Antibody for Age-related Macular Degeneration | 000 | 1 | NIH | 1/30/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $895,787 ) |
| | 2016 | 2016 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY021973 | Developing A Novel Therapy for Diabetic Retinopathy | 000 | 3 | NIH | 8/31/2016 | $710,237 |
| | 2016 | 2016 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY026326 | Fenofibrate Eye Drop for the Treatment of Diabetic Retinopathy | 000 | 1 | NIH | 8/23/2016 | $185,550 |
|
| Issue Date FY: 2015 ( Subtotal = $1,010,308 ) |
| | 2015 | 2015 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY021973 | Developing A Novel Therapy for Diabetic Retinopathy | 000 | 2 | NIH | 9/17/2015 | $785,308 |
| | 2015 | 2015 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY025157 | A Novel Therapeutic Antibody for Age-related Macular Degeneration | 000 | 1 | NIH | 7/24/2015 | $225,000 |
|
| Issue Date FY: 2014 ( Subtotal = $225,000 ) |
| | 2014 | 2014 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY024195 | A Wnt Modulator for Treatment of Age-related Macular Degeneration | 000 | 1 | NIH | 3/31/2014 | $225,000 |
|
| Issue Date FY: 2013 ( Subtotal = $926,459 ) |
| | 2013 | 2013 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY018989 | SAFETY AND TOXICOLOGY STUDIES OF CLT-005 AS A THERAPEUTIC FOR DIABETIC MACULAR ED | 000 | 4 | NIH | 1/25/2013 | $680,041 |
| | 2013 | 2013 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY021973 | DEVELOPING A NOVEL THERAPY FOR DIABETIC RETINOPATHY | 000 | 1 | NIH | 2/18/2013 | $246,418 |
|
| Issue Date FY: 2012 ( Subtotal = $1,104,798 ) |
| | 2012 | 2012 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY018989 | SAFETY AND TOXICOLOGY STUDIES OF CLT-005 AS A THERAPEUTIC FOR DIABETIC MACULAR ED | 000 | 3 | NIH | 2/7/2012 | $873,711 |
| | 2012 | 2012 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY021683 | A SMALL MOLECULE TARGETING WNT PATHWAY FOR TREATMENT OF DIABETIC RETINOPATHY | 000 | 1 | NIH | 4/9/2012 | $231,087 |
|
| Issue Date FY: 2011 ( Subtotal = $1,649,726 ) |
| | 2011 | 2011 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY021074 | NOVEL EMULSION-BASED FORMULATION OF THE ANTI-GLAUCOMA MSH-1001 FOR IMPROVED TOPIC | 000 | 1 | NIH | 8/15/2011 | $287,947 |
| | 2011 | 2011 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY020059 | MULTITARGETED THERAPY FOR AGE-RELATED MACULAR DEGENERATION | 000 | 1 | NIH | 6/20/2011 | $265,992 |
| | 2011 | 2011 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY018989 | SAFETY AND TOXICOLOGY STUDIES OF CLT-005 AS A THERAPEUTIC FOR DIABETIC MACULAR ED | 000 | 2 | NIH | 1/17/2011 | $1,095,787 |
|
| Issue Date FY: 2009 ( Subtotal = $1,135,025 ) |
| | 2009 | 2009 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY019425 | DEVELOPMENT OF A NOVEL ANTI-INFLAMMATORY TREATMENT FOR CLINICAL MANAGEMENT OF END | 000 | 1 | NIH | 6/26/2009 | $227,286 |
| | 2009 | 2009 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY019417 | NOVEL ANTIOXIDANTS FOR TREATMENT OF DIABETIC RETINOPATHY | 000 | 1 | NIH | 4/9/2009 | $248,094 |
| | 2009 | 2009 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY017790 | SUSTAINED DELIVERY OF LINOMIDE-5 FOR DIABETIC RETINOPATHY AND MACULAR DEGENERATIO | 000 | 3 | NIH | 3/3/2009 | $659,645 |
|
| Issue Date FY: 2008 ( Subtotal = $2,141,432 ) |
| | 2008 | 2008 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY018989 | A NOVEL STAT3 INHIBITOR FOR TREATING RETINAL INFLAMMATION AND NEOVASCULARIZATION | 000 | 1 | NIH | 7/21/2008 | $241,279 |
| | 2008 | 2008 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY018301 | NANOTECHNOLOGY FOR TREATMENT OF DIABETIC RETINOPATHY | 000 | 2 | NIH | 8/29/2008 | $570,438 |
| | 2008 | 2008 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY017229 | A NOVEL THALIDOMIDE ANALOG FOR THE TREATMENT OF DIABETIC MACULAR EDEMA | 000 | 3 | NIH | 7/31/2008 | $390,326 |
| | 2008 | 2008 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY017790 | SUSTAINED DELIVERY OF LINOMIDE-5 FOR DIABETIC RETINOPATHY AND MACULAR DEGENERATIO | 000 | 2 | NIH | 3/3/2008 | $729,032 |
| | 2008 | 2008 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY018774 | DEVELOPMENT OF A GENETIC CNV MODEL FOR AGE-RELATED MACULAR DEGENERATION | 000 | 1 | NIH | 1/14/2008 | $210,357 |
|
| Issue Date FY: 2007 ( Subtotal = $1,257,712 ) |
| | 2007 | 2007 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R44EY017229 | A NOVEL THALIDOMIDE ANALOG FOR THE TREATMENT OF DIABETIC MACULAR EDEMA | 000 | 2 | NIH | 9/20/2007 | $449,845 |
| | 2007 | 2007 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY018301 | NANOTECHNOLOGY FOR TREATMENT OF DIABETIC RETINOPATHY | 000 | 1 | NIH | 9/30/2007 | $570,438 |
| | 2007 | 2007 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY018270 | NOVEL COMBRETASTATIN A4 ANALOGS FOR TREATMENT OF RETINAL NEOVASCULARIZATION | 000 | 1 | NIH | 7/19/2007 | $237,429 |
|
| Issue Date FY: 2006 ( Subtotal = $382,044 ) |
| | 2006 | 2006 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY017790 | NOVEL LINOMIDE ANALOG FOR TREATMENT OF DIABETIC RETINOPATHY | 000 | 1 | NIH | 8/14/2006 | $248,294 |
| | 2006 | 2006 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY017229 | COCKTAIL OF ANGIOGENIC INHIBITORS FOR THE TREATMENT OF DIABETIC MACULAR EDEMA | 000 | 1 | NIH | 4/24/2006 | $133,750 |
|
| Issue Date FY: 2005 ( Subtotal = $433,350 ) |
| | 2005 | 2005 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY016627 | NEW THALIDOMIDE ANALOGS FOR RETINAL NEOVACULARIZATION | 000 | 1 | NIH | 6/10/2005 | $149,800 |
| | 2005 | 2005 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY016921 | PEPTIDE EYEDROPS FOR THE TREATMENT OF DIABETIC RETINOPATHY | 000 | 1 | NIH | 9/19/2005 | $133,750 |
| | 2005 | 2005 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY016298 | TREATMENT OF RETINAL VASCULAR LEAKAGE USING ANGIOSTATIN | 000 | 1 | NIH | 7/22/2005 | $149,800 |
|
| Issue Date FY: 2004 ( Subtotal = $100,000 ) |
| | 2004 | 2004 | CHARLESSON LLP | POST OFFICE BOX 14103 | OKLAHOMA CITY | OK | 73113 | OKLAHOMA | USA | R43EY015581 | RELEASE OF ANGIOGENIC INHIBITORS FOR MACULAR EDEMA | 000 | 1 | NIH | 9/27/2004 | $100,000 |
|
|
